Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tom Fang

Gastroenterology Reno, NV Medical Doctor

NPI 1053584631 CMS profile 820248

10619 Professional Cir, Reno, NV 89521

Open in the dashboard

General payments

$2,532

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tom Fang of Reno, NV is reported in the CMS Open Payments database as having received $2,532 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $871 32
2024 General $291 10
2023 General $433 8
2022 General $402 12
2021 General $158 3
2020 General $27 2
2019 General $351 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tom Fang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Tom Fang were reported at $871. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Tom Fang Gastroenterology median Middle half National median
2019 $351 $417 $126–$1,100 $163
2020 $27 $224 $74–$624 $114
2021 $158 $352 $106–$1,054 $132
2022 $402 $448 $129–$1,270 $149
2023 $433 $533 $150–$1,390 $160
2024 $291 $605 $160–$1,606 $164
2025 $871 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $618 10 payments
  2. AbbVie, Inc. $499 28 payments
  3. Ipsen Biopharmaceuticals, Inc $170 4 payments
  4. Genzyme Corporation $142 5 payments
  5. GlaxoSmithKline, LLC. $125 1 payment
  6. Covidien LP $120 1 payment
  7. Phathom Pharmaceuticals, Inc. $116 1 payment
  8. Regeneron Healthcare Solutions, Inc. $113 1 payment
  9. Gilead Sciences, Inc. $111 1 payment
  10. Janssen Scientific Affairs, LLC $109 1 payment
  11. Other $411 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,515 71 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $275 14 payments
  2. SKYRIZI Immunology $186 9 payments
  3. IQIRVO $170 4 payments
  4. DUPIXENT $142 5 payments
  5. SKYRIZI Immunology $137 4 payments
  6. BEXSERO $125 1 payment
  7. EXALT Model D $122 1 payment
  8. PillCam $120 1 payment
  9. VOQUEZNA $116 1 payment
  10. Bylvay $114 1 payment
  11. Other $1,450 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

920

Median for Gastroenterology: 569

Drug cost

$165,432

Median for Gastroenterology: $104,976

Branded share of claims

36.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 16 $63,678
Xifaxan Rifaximin Brand 11 $29,013
Mesalamine Generic 38 $24,836
Linzess Linaclotide Brand 28 $24,291
Ursodiol Generic 20 $4,667
Pantoprazole Sodium Generic 211 $4,000
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 195 $3,354
Sucralfate Generic 61 $3,088
Omeprazole Generic 120 $2,607
Colestipol Hcl Generic 12 $1,086

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$155,021

Medicare's payments for the services billed

Medicare patients

654

Average age 73

Services billed

1,411

341 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 42%
Diabetes 23%
Ischemic heart disease 20%
Chronic kidney disease 17%
Cancer 17%
Depression 16%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $25
$25 — —
DUPIXENT
  • GENZYME CORPORATION $21
$21 — —
RINVOQ
  • AbbVie, Inc. $15
$15 — —
SKYRIZI
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record